Company news

InMed Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

InMed Launches Cannabicitran (CBT), Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

January 18, 2022

InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook

January 4, 2022

InMed Pharmaceuticals Announces Publication of Peer-Reviewed Article on the Use of CBN as a Potential Treatment for Glaucoma

December 19, 2021

InMed Announces Results of 2021 Annual General Meeting

December 16, 2021

InMed Pharmaceuticals Reports First Quarter Fiscal 2022 Financial Results and Provides Business Update

November 9, 2021

InMed Pharmaceuticals Files PCT Patent Application for Treating Neurodegenerative Disease Using a Rare Cannabinoid

November 2, 2021

InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids

October 12, 2021

InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa

September 29, 2021

InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update

September 23, 2021

InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids

September 12, 2021

InMed Pharmaceuticals Signs Non-binding Letter of Intent to Acquire BayMedica, a Commercial Manufacturer of Rare Cannabinoids

June 28, 2021

InMed Pharmaceuticals Announces $12 Million Private Placement Priced At-the-Market under Nasdaq Rules

June 28, 2021

InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production

June 16, 2021

InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results

May 12, 2021

InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

April 27, 2021

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

April 26, 2021

InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™

April 25, 2021

InMed Announces Closing of US$4.5 Million Private Placement

February 15, 2021

InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results

February 10, 2021

InMed Announces US$4.5 Million Private Placement

February 4, 2021

InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

January 7, 2021

InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids

December 2, 2020

InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

November 24, 2020

InMed Announces Election of Directors

November 23, 2020

InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics

November 17, 2020

InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering

November 15, 2020

InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results

November 12, 2020

InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"

November 11, 2020

← Newer news releases

Calls

Decks

The 5 newest of 33 decks. Every deck is listed under its year.